Search

Your search keyword '"Wechalekar, Ashutosh"' showing total 21 results
Start Over Author "Wechalekar, Ashutosh" Journal amyloid
21 results on '"Wechalekar, Ashutosh"'

1. Refining prognostication in systemic AL amyloidosis: limited value of dFLC.

Author

Khwaja, Jahanzaib, Ravichandran, Sriram, Bomsztyk, Joshua, Cohen, Oliver, Foard, Darren, Martinez – Naharro, Ana, Venneri, Lucia, Fontana, Marianna, Whelan, Carol, Hawkins, Philip N., Gillmore, Julian D., Lachmann, Helen J., Mahmood, Shameem, and Wechalekar, Ashutosh

Subjects
GLOBAL longitudinal strain, SURVIVAL rate, IMMUNOGLOBULIN light chains, SYSTOLIC blood pressure, LEARNING curve, CARDIAC amyloidosis
Abstract

The document discusses the refinement of prognostication in systemic AL amyloidosis, a protein misfolding disorder leading to organ failure. Traditional biomarkers and functional assessments like 6MWD and GLS were found to be predictive of patient survival. The study suggests that in the current treatment era, GLS, 6MWD, and modified Mayo staging are more relevant predictors of overall outcome compared to dFLC levels. The findings highlight the importance of functional assessments in predicting survival in AL amyloidosis patients. [Extracted from the article]

Published
2024
Full Text
View/download PDF

2. A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis

Author

Ravichandran, Sriram, primary, Hall, Andrew, additional, Jenner, Matthew, additional, Garg, Mamta, additional, Kishore, Bhuvan, additional, Lachmann, Helen, additional, Gillmore, Julian, additional, Pitchford, Alexandra, additional, Oughton, Jamie B., additional, Mahmood, Shameem, additional, Sachchithantham, Sajitha, additional, Hawkins, Philip, additional, Brown, Sarah, additional, and Wechalekar, Ashutosh, additional

Published
2023
Full Text
View/download PDF

3. Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study

Author

Kumar, Shaji, primary, Dispenzieri, Angela, additional, Bhutani, Divaya, additional, Gertz, Morie, additional, Wechalekar, Ashutosh, additional, Palladini, Giovanni, additional, Comenzo, Raymond, additional, Fonseca, Rafael, additional, Jaccard, Arnaud, additional, Kastritis, Efstathios, additional, Schönland, Stefan, additional, la Porte, Charles, additional, Pei, Huiling, additional, Tran, NamPhuong, additional, and Merlini, Giampaolo, additional

Published
2023
Full Text
View/download PDF

4. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group

Author

Wechalekar, Ashutosh D., primary, Cibeira, M. Teresa, additional, Gibbs, Simon D., additional, Jaccard, Arnaud, additional, Kumar, Shaji, additional, Merlini, Giampaolo, additional, Palladini, Giovanni, additional, Sanchorawala, Vaishali, additional, Schönland, Stefan, additional, Venner, Christopher, additional, Boccadoro, Mario, additional, and Kastritis, Efstathios, additional

Published
2022
Full Text
View/download PDF

5. The experience of hereditary apolipoprotein A-I amyloidosis at the UK National Amyloidosis Centre

Author

Cohen, Oliver C., primary, Blakeney, Iona J., additional, Law, Steven, additional, Ravichandran, Sriram, additional, Gilbertson, Janet, additional, Rowczenio, Dorota, additional, Mahmood, Shameem, additional, Sachchithanantham, Sajitha, additional, Wisniowski, Brendan, additional, Lachmann, Helen J., additional, Whelan, Carol J., additional, Martinez-Naharro, Ana, additional, Fontana, Marianna, additional, Hawkins, Philip N., additional, Gillmore, Julian D., additional, and Wechalekar, Ashutosh D., additional

Published
2022
Full Text
View/download PDF

6. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group.

Author

Wechalekar, Ashutosh D., Cibeira, M. Teresa, Gibbs, Simon D., Jaccard, Arnaud, Kumar, Shaji, Merlini, Giampaolo, Palladini, Giovanni, Sanchorawala, Vaishali, Schönland, Stefan, Venner, Christopher, Boccadoro, Mario, and Kastritis, Efstathios

Subjects
*CANCER chemotherapy, *AMYLOIDOSIS, *EXPERT evidence, *CARDIAC amyloidosis, *DARATUMUMAB, *SYMPTOMS
Abstract

This guideline has been developed jointly by the European Society of Haematology and International Society of Amyloidosis recommending non-transplant chemotherapy treatment for patients with AL amyloidosis. A review of literature and grading of evidence as well as expert recommendations by the ESH and ISA guideline committees. The recommendations of this committee suggest that treatment follows the clinical presentation which determines treatment tolerance tempered by potential side effects to select and modify use of drugs in AL amyloidosis. All patients with AL amyloidosis should be considered for clinical trials where available. Daratumumab-VCD is recommended from most untreated patients (VCD or VMDex if daratumumab is unavailable). At relapse, the two guiding principles are the depth and duration of initial response, use of a class of agents not previously exposed as well as the limitation imposed by patients' fitness/frailty and end organ damage. Targeted agents like venetoclax need urgent prospective evaluation. Future prospective trials should include advanced stage patients to allow for evidence-based treatment decisions. Therapies targeting amyloid fibrils or those reducing the proteotoxicity of amyloidogenic light chains/oligomers are urgently needed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

9. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients

Author

Milani, Paolo, primary, Sharpley, Faye, additional, Schönland, Stefan O., additional, Basset, Marco, additional, Mahmood, Shameem, additional, Nuvolone, Mario, additional, Kimmich, Christoph, additional, Foli, Andrea, additional, Sachchithanantham, Sajitha, additional, Merlini, Giampaolo, additional, Wechalekar, Ashutosh, additional, Palladini, Giovanni, additional, and Hegenbart, Ute, additional

Published
2020
Full Text
View/download PDF

10. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis

Author

Cohen, Oliver C., primary, Brodermann, Maximillian H., additional, Blakeney, Iona J., additional, Mahmood, Shameem, additional, Sachchithanantham, Sajitha, additional, Ravichandran, Sriram, additional, Law, Steven, additional, Lachmann, Helen J., additional, Whelan, Carol J., additional, Popat, Rakesh, additional, Rabin, Neil, additional, Yong, Kwee, additional, Kyriakou, Charalampia, additional, Shah, Raakhee, additional, Cheesman, Simon, additional, Worthington, Sarah, additional, Hawkins, Philip, additional, Gillmore, Julian D., additional, and Wechalekar, Ashutosh D., additional

Published
2020
Full Text
View/download PDF

12. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.

Author

Sanchorawala, Vaishali, Boccadoro, Mario, Gertz, Morie, Hegenbart, Ute, Kastritis, Efstathios, Landau, Heather, Mollee, Peter, Wechalekar, Ashutosh, and Palladini, Giovanni

Subjects
STEM cell transplantation, AMYLOIDOSIS, MULTIPLE myeloma, PLASMA cells, CANCER chemotherapy
Abstract

AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in multiple myeloma. This application has evolved significantly over the past three decades. These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. These guidelines are developed by the experts in the field on behalf of the stem cell transplant working group of the International Society of Amyloidosis (ISA) and European Haematology Association (EHA). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement

Author

Manwani, Richa, primary, Page, Jo, additional, Lane, Thirusha, additional, Burniston, Maria, additional, Skillen, Annah, additional, Lachmann, Helen J., additional, Gillmore, Julian D., additional, Fontana, Marianna, additional, Whelan, Carol, additional, Hawkins, Philip N., additional, Wagner, Thomas, additional, and Wechalekar, Ashutosh D., additional

Published
2018
Full Text
View/download PDF

15. Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study

Author

Phillips, Elizabeth H., primary, Nash, Stephen, additional, Adedayo, Toyin, additional, Whelan, Carol J., additional, Fontana, Marianna, additional, Mahmood, Shameem, additional, Lachmann, Helen J., additional, Gillmore, Julian D., additional, Smith, Paul, additional, Clifton-Hadley, Laura, additional, Hawkins, Philip N., additional, and Wechalekar, Ashutosh D., additional

Published
2017
Full Text
View/download PDF

16. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre

Author

Lane, Thirusha, primary, Pinney, Jennifer H., additional, Gilbertson, Janet A., additional, Hutt, David F., additional, Rowczenio, Dorota M., additional, Mahmood, Shameem, additional, Sachchithanantham, Sajitha, additional, Fontana, Marianna, additional, Youngstein, Taryn, additional, Quarta, Candida C., additional, Wechalekar, Ashutosh D., additional, Gillmore, Julian D., additional, Hawkins, Philip N., additional, and Lachmann, Helen J., additional

Published
2017
Full Text
View/download PDF

18. A good clonal response to chemotherapy in AL amyloidosis is associated with improved quality of life and function at 1 year

Author

Carter, John-Paul, primary, Foard, Darren, additional, Rannigan, Lisa, additional, Aliaz, Kamela, additional, Mahmood, Shameem, additional, Sachchithanantham, Sajitha, additional, Fontana, Marianna, additional, Quarta, Cristina, additional, Martinez De Azcona Naharro, Ana, additional, Youngstein, Taryn, additional, Rezk, Tamer, additional, Wechalekar, Ashutosh, additional, Whelan, Carol, additional, Lachmann, Helen, additional, Hawkins, Philip, additional, Gillmore, Julian, additional, and Lane, Thirusha, additional

Published
2017
Full Text
View/download PDF

20. Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis.

Author

Ross, James C., Hutt, David F., Burniston, Maria, Page, Joanne, Steeden, Jennifer A., Gillmore, Julian D., Wechalekar, Ashutosh D., Hawkins, Philip N., and Fontana, Marianna

Subjects
TRANSTHYRETIN, CARDIAC amyloidosis, RADIOACTIVE tracers, IMAGING system equipment in medicine, AMYLOID
Abstract

Purpose: Transthyretin (ATTR) amyloidosis is a rare but serious infiltrative disease associated with a wide spectrum of morphologic and functional cardiac involvement. 99mTc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD), initially developed as a bone-seeking radiotracer, is remarkably sensitive for imaging cardiac ATTR amyloid deposits. Our aim was to investigate the feasibility and utility of estimating 99mTc-DPD uptake in myocardial tissue; this has the potential to yield reliable quantitative information on cardiac amyloid burden, which is urgently required to monitor disease progression and response to novel treatments. Methods: Three methods of quantitation were developed and tested on 74 patients with proven cardiac ATTR amyloidosis who had recently undergone 99mTc-DPD planar whole-body imaging and SPECT-CT. Quantitative results were compared to measurements of extracellular volume fraction (ECV) by cardiac magnetic resonance imaging, a validated technique for measuring amyloid burden. Results: An experienced clinician graded uptake using a widely-used visual scoring system as 1 (n = 15), 2 (n = 39) or 3 (n = 20). Linear correlations between the SPECT and ECV data (p < .001) were demonstrated. None of the methods showed that 99mTc-DPD uptake in the heart was significantly greater in patients with grade-3 uptake than in those with grade-2 uptake. Conclusions: Quantitation of 99mTc-DPD uptake in cardiac transthyretin amyloid deposits is complex and is hindered by competition for radiotracer with amyloid in skeletal muscle. The latter underlies differences in uptake between grade-2 and grade-3 patients, not cardiac uptake. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

21. Tc-DPD scintigraphy as a novel imaging modality for identification of skeletal muscle amyloid deposition in light-chain amyloidosis.

Author

Hutt, David F., Gilbertson, Janet, Quigley, Anne-Marie, and Wechalekar, Ashutosh D.

Subjects
AMYLOID, AMYLOIDOSIS, CARBOXYLIC acids, TRANSTHYRETIN, PATIENTS, DISEASE risk factors, THERAPEUTICS
Abstract

The article offers information on systemic light-chain (AL) amyloidosis involving the kidneys, heart, and liver. Topics discussed include patients with suspected cardiac amyloidosis, difficulties in determining extent of amyloid deposition outside of vital organs, and role of Tc-labeled 3,3-diphosphono-1,2-propanodicarboxylic acid as a sensitive tracer for cardiac transthyretin amyloid deposits.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results